Carrie Lynde, MD, Dermatology PGY-1, University of Toronto, Toronto, ON.
John Kraft, MD, Dermatology PGY-4, University of Toronto, Toronto, ON.
Charles Lynde, MD, FRCPC, Assistant Professor, Division of Dermatology, University of Toronto; Dermatology consultant for Metropolitan Homes for the Aged, Toronto; Markham Stouffville Hospital; Scarborough Grace Hospital, Toronto, ON.

Psoriasis is a chronic relapsing skin disease. Age of onset is bimodal with a peak in second to third decades and the sixth decade. Individuals affected by psoriasis usually complain of lower self-esteem. Choice of therapy depends on many factors, including areas affected, extent of disease, patient’s lifestyle, other health problems, and medications. Many effective therapies exist, including topicals, phototherapy, systemics, and biologicals.
Key words: psoriasis, comorbidities, topical steroids, phototherapy, biologics.

Scott R.A. Walsh PhD, MD, Division of Dermatology, Department of Medicine, Sunnybrook & Women’s College Health Sciences Centre, University of Toronto Medical School, Toronto, Ontario.

Dermatitis herpetiformis (DH) is a pruritic and chronic autoimmune blistering skin disease associated with varying degrees of gluten-induced enteropathy. Associated symptomatic celiac disease (CD) occurs in a minority of patients, but the pathogenesis of both diseases shares several features. In addition to some features of enteropathy, patients with DH also form specific antibodies to epidermal transglutaminase not typically found in patients with only CD. Although incidence is highest in middle age, because it is a life-long condition its prevalence is highest in the older population. Chronic complications of DH, including gastrointestinal lymphomas, are more likely to present in the geriatric group. Similarly, common comorbid disease associations including pernicious anemia, splenic atrophy and thyroid disease should be routinely assessed in this population. Long-term treatment of DH requires strict adherence to a gluten-free diet. Symptomatic treatment of this skin disease commonly uses dapsone to inhibit neutrophil accumulation and disease expression. Older patients may be more susceptible to toxic side effects of dapsone metabolites, and both careful patient selection and close monitoring should be undertaken with dapsone treatment.

Key words: dermatitis herpetiformis, autoimmunity, anemia, comorbidities, dapsone.